Antiviral & Antifibrotic Liver Therapy in HCV + Drinkers and Non-Drinkers

PHASE2CompletedINTERVENTIONAL

Enrollment

207

Participants

Timeline

Start Date

June 30, 2000

Primary Completion Date

December 31, 2005

Study Completion Date

December 31, 2005

Conditions

Hepatitis C

Interventions

DRUG

Polyenylphosphatidylcholine (PPC)

DRUG

Pegylated Interferon

DRUG

Ribavirin

Trial Locations (1)

Bronx VA, The Bronx

All Listed Sponsors

collaborator

National Institute on Alcohol Abuse and Alcoholism (NIAAA)

NIH

collaborator

Hoffmann-La Roche

INDUSTRY

lead

Icahn School of Medicine at Mount Sinai

OTHER

NCT00211848 - Antiviral & Antifibrotic Liver Therapy in HCV + Drinkers and Non-Drinkers | Biotech Hunter | Biotech Hunter